Always Evolving and Adapting

OTC Markets

Anthony, Linder & Cacomanolis provides lead legal counsel for OTC Market compliance. We advise on Rule 15c2-11 requirements, tiered market listings (OTCQX, OTCQB, OTCID), and the strategic pathway for up-listing to national exchanges.

OTC Market Compliance: Strategic Navigation of Tiered Trading

The OTC Markets represent a vital ecosystem for companies seeking liquidity and institutional visibility outside the national exchanges. At Anthony, Linder & Cacomanolis, we view the OTC Markets not as a secondary option, but as a strategic platform for growth and capital appreciation. Our firm provides the technical oversight required to navigate the distinct requirements of the OTCQX, OTCQB, and OTCID, advising domestic and international issuers on maintaining compliance with SEC and OTC Markets Group standards.

Our advisory model supports the specialized needs of corporate entities within the South Florida financial hub and international issuers seeking a U.S. trading presence—often as a dual-listing venue rather than an initial public entry—including those within the Japan-U.S. capital corridor. We view OTC compliance as the essential mechanism for preserving market integrity and facilitating the eventual transition to a national exchange.

Partner-led and internationally focused, ANTHONY, LINDER & CACOMANOLIS, PLLC delivers regulatory-precise corporate and securities counsel—backed by a $20B+ transaction track record and deep Japan–U.S. listing experience—to guide IPOs, de‑SPACs, M&A and complex capital raises. Our U.S. entity formation attorneys represent clients worldwide and across the U.S., including West Palm Beach and Palm Beach County (FL), Jacksonville, Miami and Tampa (FL), and Houston, San Antonio and Dallas (TX); schedule a consultation at 877-541-3263 or visit our contact page.

The Tiered Market Structure: OTCQX, OTCQB, and OTCID

The OTC Markets are structured into tiers based on a company’s financial strength, corporate governance, and level of disclosure. Anthony, Linder & Cacomanolis advises boards on the strategic selection of the most appropriate tier:

OTCQX (The Best Market): Designed for established, investor-focused companies, OTCQX requires high financial standards and sophisticated corporate governance. We manage the application process for this premier tier, advising on the prohibition of “penny stocks” and the requirement for an annual management certification.
OTCQB (The Venture Market): For early-stage and growth companies, OTCQB provides a structured reporting environment. We assist issuers in meeting the eligibility requirements, including the minimum $0.01 bid price test and the annual certification of company information and beneficial ownership.
OTCID: For companies that do not yet meet the criteria for OTCQX or OTCQB, the OTCID provides a pathway for public quotes. We focus on the technicalities of the “Current Information” status, advising management on the disclosure mandates necessary to avoid the “Expert Market” or “No Information” designations.

Rule 15c2-11 and the Current Information Requirement

A critical component of OTC market participation is compliance with SEC Rule 15c2-11. Following the 2021 amendments to the rule, broker-dealers are generally prohibited from publishing quotes for securities of issuers that do not make current information publicly available.

Anthony, Linder & Cacomanolis manages the technical workstreams required to satisfy these mandates. We advise on the preparation and publication of required financial and operational data, whether through SEC reporting or the OTC Markets Group’s Alternative Disclosure Standard (ADS). By prioritizing the “Current Information” status, we help issuers protect their market liquidity from being frozen or relegated to the Expert Market.

Disclosure Standards: SEC Reporting vs. Alternative Disclosure

We advise boards on selecting the most efficient reporting framework for their OTC listing:

SEC Reporting Issuers: Companies that file periodic reports (10-K, 10-Q, 8-K) with the SEC automatically satisfy most OTC disclosure requirements. We manage these filings to ensure they meet both SEC and OTC standards.
Alternative Disclosure Standard (ADS): For non-SEC reporting issuers, we lead the drafting of the OTC Markets Group disclosure statements. This includes the preparation of annual and quarterly reports and the oversight of “Attorney Letters” regarding the adequacy of the company’s public information.

Strategic Pathway to National Exchanges (Up-listing)

For many OTC issuers, the ultimate goal is an “up-listing” to Nasdaq or the NYSE. Anthony, Linder & Cacomanolis views OTC compliance as the rigorous training ground for this transition. We advise boards on hardening their corporate governance, improving their financial posture, and managing the reverse stock splits or capital raises often necessary to meet the initial listing requirements of a national exchange. Our methodology focuses on building the institutional-grade compliance foundation required for a successful debut on a higher tier.

The Governing Principle: Materiality in OTC Disclosure

The governance of OTC disclosure is rooted in the materiality standard. Anthony, Linder & Cacomanolis advises boards that even without a full SEC registration, the obligation to disclose all information that a reasonable investor would consider important is paramount.

We apply this standard to every disclosure statement and corporate news release. By focusing on materiality, we help management teams mitigate the risks of “market manipulation” allegations while advising on the protection of the company against the pitfalls of omissions. This disciplined approach provides a “white-label” path to maintaining the confidence of investors and regulators.

Technical Execution and Regulatory Liaison

The execution of an OTC strategy requires a solution-oriented approach that manages the intersection of SEC rules, FINRA oversight, and OTC Markets Group policy. We act as the primary liaison for our clients, managing the technicalities of legend removal, Rule 144 compliance, and the oversight of corporate actions such as name changes or share reorganizations. Working in close coordination with the company’s transfer agent and market makers, we provide the legal framework necessary for a successful and liquid public lifecycle.

Strategic Consultation for C-Suite and Boards

Maintaining an OTC listing requires a sophisticated understanding of evolving disclosure rules and market tiers. Anthony, Linder & Cacomanolis invites CEOs, CFOs, and Board Directors to engage in a high-level strategy consultation to evaluate your current OTC posture and ensure your market presence is optimized for institutional growth.

Schedule an executive strategy consultation with our senior partners to discuss your OTC Market needs by calling 877-541-3263 or visiting our contact page.